Pleural mesothelioma: Epidemiological and public health issues. Report from the second italian consensus conference on pleural mesothelioma

Medicina del Lavoro

Volumn 104, Issue 3, 2013, Pages 191-202

  Magnani, Corrado ^a   Fubini, Bice ^b   Mirabelli, Dario ^b   Bertazzi, Pier Alberto ^c   Bianchi, Claudio ^d   Chellini, Elisabetta ^e   Gennaro, Valerio ^f   Marinaccio, Alessandro ^g   Menegozzo, Massimo ^h   Merler, Enzo ⁱ   Merletti, Franco ^b   Musti, Marina ^j   Pira, Enrico ^b   Romanelli, Antonio ^k   Terracini, Benedetto ^b   Zona, Amerigo ^l  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Italian League Against Cancer   (Italy)

^e ISPO   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g DEPARTMENT OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ Local Health Authority   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k AzUSL di Reggio Emilia   (Italy)

^l ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

Asbestos; Mesothelioma; Pleura

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; HUMAN; ITALY; MESOTHELIOMA; PLEURA TUMOR; PUBLIC HEALTH;

HUMANS; ITALY; MESOTHELIOMA; PLEURAL NEOPLASMS; PUBLIC HEALTH;

EID: 84885133910     PISSN: 00257818     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Adachi S, Kawamura K, Takemoto K: A trial on the quantitative risk assessment of man-made mineral fibers by the rat intraperitoneal administration assay using the JFM standard fibrous samples. Ind Health 2001; 39: 168-174. (Pubitemid 32452465)
2. Aguilar-Madrid G, Robles-Perez E, Juarez-Perez CA, et al: Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 2010; 53: 241-251.
3. Albin M, Jakobsson K, Attewell R, et al: Mortality and cancer morbidity in cohorts of asbestos cement workers and referents. Br J Ind Med 1990; 47: 602-610. (Pubitemid 20261517)
4. Albin M, Johanssen L, Pooley FD, et al: Mineral fibres, fibrosis, and asbestos bodies in lung tissue from deceased asbestos cement workers. Br J Ind Med 1990; 47: 767- 774. (Pubitemid 20340603)
5. Albin M, Pooley FD, Stromberg U, et al: Retention patterns of asbestos fibres in lung tissue among asbestos cement workers. Occup Environ Med 1994; 51:205-211. (Pubitemid 24106170)
6. Apostolou S, Balsara BR, Testa JR, et al: Cytogenetics of malignant mesothelioma. In: Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies. New York: Springer Science & Business Media, Inc, 2006:101-111.
7. Ascoli V, Cavone D, Merler E, et al: Mesothelioma in Blood Related Subjects: Report of 11 Clusters Among 1954 Italy Cases and Review of the Literature. Am J Ind Med 2007; 50: 357-369. (Pubitemid 46786853)
8. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545. (Pubitemid 32173595)
9. Baris YI, Grandjean P: Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite. J Natl Cancer Inst 2006; 98: 414-417.
10. Barone Adesi F, Ferrante D, Bertolotti M, et al: Long- term mortality from pleural and peritoneal cancer after exposure to asbestos. Possible role of asbestos clearance. Int J Cancer 2008; 123: 912-916. (Pubitemid 352032421)
11. Berman DW, Crump KS: A meta-analysis of asbestos- related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol 2008; 38: 49-73.
12. Bernstein D., Castranova V, Donaldson K, et al: Testing of fibrous particles: short-term assays and strategies. ILSI Working Group on short term fibre testing. Inhal Toxicol 2005; 17:497-537. (Pubitemid 41166565)
13. Berry G, Rogers AJ, Pooley FD: Mesotheliomas-asbestos exposure and lung burden. LARC Scientific Publication n. 90, 1989:486-496.
14. Berry G, de Klerk NH, Reid A, et al: Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Environ Med 2004; 61: el4.
15. Berry G, Newhouse ML, Wagner JC: Mortality from all cancers of asbestos factory workers in east London 1933-80. Occup Environ Med 2000; 57: 782-785.
16. Bertazzi PA: Descriptive Epidemiology of Malignant Mesothelioma. Med Lav 2005; 96:287-303. (Pubitemid 44783812)
17. Betti M, Ferrante D, Padoan M, et al: XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study. Mutat Res 2011; 708:11-20.
18. Bianchi C, Bianchi T: Susceptibility and resistance in the genesis of asbestos-related mesothelioma. Indian J Occup Environ Med 2008; 12: 57-60.
19. Boffetta P, Stayner LT: Pleural and peritoneal neoplasms. In Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention. Third edition. Oxford University Press, 2006: 659-673.
20. Bott M, Brevet M, Taylor BS, et al. The nuclear deu- biquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668-672.
21. Broaddus VC, Everitt JI, Black B, Kane AB: Nonneoplastic and neoplastic pleural endpoints following fiber exposure. J Toxicol Environ Hit B 2011; 14: 153- 178.
22. Bruno C, Comba P, Zona A. Adverse health effects of fluoro-edenitic fibers: epidemiological evidence and public health priorities. Ann N Y Acad Sci 2006; 1076: 778-783. (Pubitemid 44955307)
23. Burdorf A, Jarvholm B, Englund A: Explaining differences in incidence rates of pleural mesothelioma between Sweden and the Netherlands. Int J Cancer 2005; 113:298-301. (Pubitemid 39628321)
24. Carbone M, Baris YI, Bertino P, et al: Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA 2011; 108: 13618-13623.
25. Carbone M, Ly MH, Dodson RF, et al: Malignant mesothelioma: facts, myths and hypotheses. J cellular Physiology 2011 DOI 10.1002/jcp.22724.
26. Case BW, Abraham JL, Meeker G, et al: Applying definitions of "asbestos" to environmental and "low dose" exposure levels and health effects, particularly malig-nant mesothelioma. J Toxicol Environ Health B Crit Rev 2011; 14: 3-39.
27. Christensen BC, Houseman EA, Godleski JJ, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69: 227-234.
28. Chrysotile Asbestos Expert Panel. Chrysotile Asbestos Consensus Statement and Summary Montreal, Quebec November 13-14, 2007.
29. Churg A, Wright JL: Persistence of natural mineral fibers in human lungs: an overview. Environ Health Perspect 1994; 102 (Suppl 5): 229-233. (Pubitemid 24364859)
30. de Klerk NH, Armstrong BK, Musk AW, Hobbs MS: Cancer mortality in relation to measures of occupational exposure to crocidolite at Wittenoom Gorge in Western Australia. Br J Ind Med 1989; 46: 529-536. (Pubitemid 19202923)
31. de Klerk NH, Musk AW, Williams V, et al: Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia. Am J Ind Med 1996; 30: 579-587. (Pubitemid 26372541)
32. Donaldson K, Murphy F, Duffin R, Poland CA: Asbestos, carbon nanotubes and the pleural mesotheli- um: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010; 7: 5- 22.
33. EU. Directive 2009/148/EC of the European Parliament and of the Council of 30 November 2009 on the protection of workers from the risks related to exposure to asbestos at work Official Journal of the European Union, 16.12.2009 L 330/28.
34. Ferrante D, Bertolotti M, Todesco A, et al: Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect 2007; 115:1401-1405. (Pubitemid 47618081)
35. Finkelstein MM, Dufresne A. Inferences on the kinetics of asbestos deposition and clearance among chrysotile miners and millers. Am J Ind Med 1999; 35: 401-412. (Pubitemid 29122292)
36. Finkelstein MM, Meisenkothen C: Malignant mesothelioma among employees of a Connecticut factory that manufactured friction materials using chrysotile asbestos Ann Occup Hyg 2010; 54: 692-496.
37. Finkelstein MM: Analysis of the exposure-response relationship for mesothelioma among asbestos-cement factory workers. Ann N Y Acad Sci 1991; 643: 85-89.
38. Gatta G, Ciccolallo L, Kunkler I, et al: Survival from rare cancer in adults: a population-based study. Lancet Oncol 2006; 7:132-140. (Pubitemid 43159499)
39. Gee GV, Stanifer ML, Christensen BC, et al: SV40 associated miRNAs are not detectable in mesotheliomas. Br J Cancer 2010; 103: 885-888.
40. Gemignani F, Neri M, Bottari F, et al: Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. Mutat Res 2009; 671: 76-83.
41. Goodman JE, Nascarella MA, Valberg PA. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 2009; 20:1237-1254.
42. Harding AH, Darnton AJ: Asbestosis and Mesothelioma Among British Asbestos Workers (1971-2005). Am J Ind Med 2010; 53:1070-1080.
43. HEI Health Effects Institute - Asbestos Research. Asbestos in public and commercial buildings. Health Effects Institute - Asbestos Research. Cambridge (MA); 1991.
44. Hodgson JT, Darnton A: The Quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44: 565-601.
45. Howel D, Gibbs A, Arblaster L, et al: Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med 1999; 56:51-58. (Pubitemid 29103649)
46. Huang SXL, Jaurand MC, Kamp DW, et al: Role of Mutagenicity in Mineral Fiber-Induced Carcinogenicity and other Diseases. J Toxicol Environ Health B Crit Rev 2011; 14:179-245.
47. International Agency for Research on Cancer. A review of Human carcinogens: Metals, arsenic, dusts, and fibres. IARC, Lyon, 2012 (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 100 C).
48. International Agency for Research on Cancer: asbestos. IARC, Lyon, 1977. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 14).
49. International Agency for Research on Cancer: IARC Monographs on the evaluation of the carcinogenic risk of chemicals to man: Preamble. IARC, Lyon 2006. disponibile on line all'indirizzo: http://monographs.iarc.fr/ENG/Preamble/ CurrentPreamble.pdf (accessed on November 25th, 2011).
50. International Agency for Research on Cancer: Man- made mineral fibres. IARC, Lyon, 2002. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 81).
51. Iwatsubo Y, Pairon JC, Boutin C, et al: Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case- control study. Am J Epidemiol 1998; 148:133-142. (Pubitemid 128721148)
52. Johnson NF, Hahn FF: Induction of mesothelioma after intrapleural inoculation of F344 rats with silicon carbide whiskers or continuous ceramic filaments. Occup Environ Med 1996; 53: 813-816. (Pubitemid 26425965)
53. Kanarek MS. Mesothelioma from chrysotile asbestos: update. Ann Epidemiol 2011; 21: 688-697.
54. Kane AB: Mechanisms of Mineral Fibre Carcinogenesis. In Kane AB, Boffetta P, Saracci R, Wilbourn J.D. (Eds): Vol. 140. IARC, 1996.
55. Kjaerheim K, Rae OD, Waterboer T, et al: Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer 2007; 120: 2459-2465. (Pubitemid 46642135)
56. Langer AM: Health experience of some US and Canadian workers exposed to asbestos: foundation for risk assessment. In Nolan RP, Langer AM, Ross M, et al (eds): The health effects of chrysotile. Canadian Mineralogist Special Publication 5, 2001: 9-20.
57. Lee KP, Barras CE, Griffith FD, et al: Comparative pulmonary responses to inhaled inorganic fibers with asbestos and fiberglass Environ Res 1981; 24:167-191. (Pubitemid 11141321)
58. Liddell FD, McDonald AD, McDonald JC: The 1891- 1920 birth cohort of Quebec chrysotile miners and millers: development from 1904 and mortality to 1992. Ann Occup Hyg 1997; 41:13-36. (Pubitemid 27092316)
59. Lundstig A, Dejmek A, Eklund C, et al: No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. Anticancer Res 2007; 27: 4159-4162.
60. Magnani C: SV40, genetic polymorphism and mesothelioma. Pathhological and epidemiologiccal evidence. Med Lav 2005; 96: 347-353. (Pubitemid 44783817)
61. Magnani C, Ferrante D, Barone-Adesi F, et al. Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. Occup Environ Med. 2008; 65:164-170. (Pubitemid 351327453)
62. Manning CB, Vallyathan V, Mossman BT: Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol 2002; 2:191-200. (Pubitemid 34075410)
63. Mantovani A, Allavena P, Sica A, et al: Cancer-related inflammation. Nature 2008; 454:436-444.
64. Marinaccio A, et al (eds): Registro Nazionale Mesote- liomi. Quarto Rapporto. Roma. Istituto Superiore per la Prevenzione e la Sicurezza del Lavoro. ISBN-978- 88-7484-281-0. INAIL, Roma, 2012. Online: http://www.inail.it/ repository/ContentManagement/information/P60775387/ReNam.pdf.
65. Marinaccio A, Binazzi A, Cauzillo G, et al: Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43:2722-2728. (Pubitemid 350161848)
66. Marinaccio A, Binazzi A, Di Marzio D, et al: Incidence of extrapleural malignant mesothelioma and asbestos exposure, from Italian National register. Occup Environ Med 2010; 67: 760-765.
67. Marinaccio A, Binazzi A, Di Marzio D, et al: Pleural malignant mesothelioma epidemic. Incidence, modalities of asbestos exposure and occupations involved from the Italian national register. Int J Cancer 2012; 130: 2146-2154.
68. Marinaccio A, Montanaro F, Mastrantonio M, et al: Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer 2005; 115:142-147. (Pubitemid 40559680)
69. Marinaccio A, Nesti M & Regional Operational Centers: Analysis of survival for mesothelioma cases in the Italian register (ReNaM). Eur J Cancer 2003; 39:1290- 1295. (Pubitemid 36579202)
70. Mastrantonio M, Belli S, Binazzi A, et al: La mortalita per tumore maligno della pleura nei comuni italiani (1988-1997) Rapporti ISTISAN 02/12. Istituti Superiore di Sanita, Roma. ISSN 1123-3117.
71. Maule M, Merletti F, Mirabelli D, La Vecchia C: Spatial variation of mortality for common and rare cancers in Piedmont, Italy, from 1980 to 2000: a Bayesian approach. Eur J Cancer Prev 2006; 15:108-116. (Pubitemid 44145595)
72. McDonald JC, Armstrong B, Case B, et al: Mesothelioma and asbestos fiber type. Evidence from lung tissue analyses. Cancer 1989; 63:1544-1547. (Pubitemid 19093278)
73. McDonald JC, Armstrong BG, Edwards CW, et al: Case-referent survey of young adults with mesothelioma: I. Lung fibre analyses. Ann Occup Hyg 2001; 45:513-518. (Pubitemid 32907264)
74. McDonald JC, Harris JM, Berry G: Sixty years on: the price of assembling military gas masks in 1940. Occup Environ Med 2006; 63: 852-855. (Pubitemid 46024936)
75. Merler E, Bressan V, Bilato AM, Marinaccio A, Grup- po regionale veneto sui mesoteliomi maligni: I fattori che influenzano in Italia la domanda e il riconoscimen- to dei mesoteliomi di origine professionale. Epidemiol Prev 2011; 35: 331-338.
76. Mirabelli D, Cavone D, Merler E, et al: Non-occupa tional exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med 2010; 67: 792-794.
77. Mirabelli D, Roberti S, Gangemi M, et al: Survival of peritoneal malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009; 124:194-200.
78. Miserocchi G, Sancini G, Mantegazza F, et al: Translocation pathways for inhaled asbestos fibers. Environ Health 2008; 7: 4.
79. Montanaro F, Bray F, Gennaro V, et al: Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 2003; 14: 791-803. (Pubitemid 37463893)
80. Montanaro F, Rosato R, Gangemi M, et al: Survival of pleural malignant mesothelioma in Italy: A population- based study. Int J Cancer 2009; 124:201-207.
81. Moolgavkar SH, Meza R, Turim J: Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009; 20:935-944.
82. Mowe G, Gylseth B, Hartveit F, Skaug V: Fiber Concentration in Lung Tissue of Patients With Malignant Mesothelioma: A Case-Control Study. Cancer 1985; 56:1089-1093. (Pubitemid 15003492)
83. Muller J, Delos M, Panin N, et al: Absence of carcinogenic response to multiwall carbon nanotubes in a 2 year bioassay in the peritoneal cavity of the rat. Toxicol Sci 2009; 110:442-448.
84. Murthy SS, Testa JR: Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180: 150-157. (Pubitemid 29297191)
85. Musk AW, deKlerk NH, Olsen N, et al: Mortality in Miners and Millers of Crocidolite in Western Australia: Follow-up to 1999. Ann Occup Hyg 2002; 46 (Suppl 1): 90-92.
86. Musk AW, deKlerk NH, Reid A, et al: Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom. Occup Environ Med 2008; 65:541-543.
87. Neri M, Ugolini D, Dianzani I, et al: Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res 2008; 659: 126- 136.
88. Newhouse ML, Berry G: Predictions of mortality from mesothelial tumours in asbestos factory workers. Br J Ind Med 1976; 33:147-151.
89. NIOSH (National Institute for Occupational Safety and Health). 2011. Current intelligence bulletin: asbestos fibers and other elongate mineral particles: state of the science and roadmap for research, version 4. April 2011. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, http://www.cdc.gov/niosh/docket/archive/docket099C.html.
90. NTP - National Toxicology Program. Report on carcinogens. Background document for Glass wool fibres. US dep. Health. Research Triangle Park, 2009.
91. Pan XL, Day HW, Wang W, et al: Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172:1019-1025. (Pubitemid 41476540)
92. Paoletti L, Bruni BM: Size distribution of amphibole fibres from lung and pleural tissues sampled from mesothelioma cases due to environmental exposure. Med Lav 2009; 100:11-20.
93. Park E-K, Takahashi K, Hoshuyama T, et al: 2011. Global Magnitude of Reported and Unreported Mesothelioma. Environ Hit Perspect 2011; 119: 514- 518.
94. Pelucchi C, Malvezzi M, La Vecchia C, et al: The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90:1022-1024. (Pubitemid 38495822)
95. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 1999; 79: 666- 672. (Pubitemid 29046253)
96. Peto J, Doll R, Hermon C, et al: Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg 1985; 29:305-355. (Pubitemid 16220683)
97. Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: implications for models of carcinogenicity and risk assessment. Br J Cancer 1982; 45:124-135. (Pubitemid 12207760)
98. Peto J: The hygiene standard for chrysotile asbestos. Lancet 1978; 1: 484-489. (Pubitemid 8286042)
99. Pinto C, Novello S, Torri V, et al: Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations. Cancer Treat Rev. 2012 Dec 11. doi:pii: S0305-7372(12) 00236-8.10.1016/j.ctrv.2012.11. 004.
100. Pira E, Pelucchi C, Piolatto PG, et al: Mortality from cancer and other causes in the Balangero cohort of chrysotile asbestos miners. Occup Environ Med 2009; 66: 805-809.
101. Poland CA, Duffin R, Kinloch I, et al: Carbon nan- otubes introduced into the abdominal cavity of mice show asbestoslike pathogenicity in a pilot study. Nat Nanotechnol 2008; 3:423-428.
102. Reid A, Berry G, Heyworth J, et al: Predicted mortality from malignant mesothelioma among women exposed to blue asbestos at Wittenoom, Western Australia. Occup Environ Med 2009; 66:169-174.
103. Rodelsperger K, Jockel KH, Pohlabeln H, et al: Asbestos and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: results from a German hospital-based case-control study. Am J Ind Med 2001; 39:262-275. (Pubitemid 32176365)
104. Rodelsperger K, Woitowitz HJ, Briickel B, et al: Dose-response relationship between amphibole fiber lung burden and mesothelioma. Cancer Detect Prev 1999; 23:183-193. (Pubitemid 29233603)
105. Rogers AJ, Leigh J, Berry G, et al: Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. A case-control study. Cancer 1991; 67:1912-1920.
106. Russo A, Bisanti L. Rapporto sui tumori a Milano. ASL della Citta di Milano. Milano: Ed. Zadig, 2007: XXXI- II-IV, 74-79.
107. Sakamoto Y, Nakae D, Fukumori N, et al: Induction of mesothelioma by a single intrascrotal administration of multi-wallcarbon nanotube in intact male fis- cher 344 rats. J Toxicol Sci 2009; 34: 65-76.
108. Selikoff IJ, Seidman H: Asbestos-associated deaths among insulation workers in the United States and Canada, 1967-1987. Ann N Y Acad Sci 1991; 643:1- 14.
109. Shah KV: SV40 and human cancer: a review of recent data. Int J Cancer 2007; 120:215-223. (Pubitemid 44956830)
110. Stanton MF, Layard M, Tegeris A, et al: Relation of particles dimension to carcinogenicity in amphibole asbestoses and fibrous minerals. JNCI 1981; 67: 965- 975. (Pubitemid 12252082)
111. Takagi A, Hirose A, Nishimura T, et al: Induction of mesothelioma in p53 +/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008; 33:105-116. (Pubitemid 351340768)
112. Tan E, Warren N: Mesothelioma mortality in Great Britain. The revised risk and two-stage clonal expansion models. Health and Safety Excutive. (HSE) 2011; Research Report 876.
113. Terracini B: The scientific basis of a total asbestos ban. Med Lav 2006; 97:383-392.
114. Testa JR, Cheung M, Pei J, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022-1025.
115. Tuomi T, Huuskonen MS, Virtamo M, et al: Relative risk of mesothelioma associated with different levels of exposure to asbestos. Scand J Work Environ Health 1991; 17:404-408.
116. Ugolini D, Neri M, Ceppi M, et al: Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. Mutat Res 2008; 658:162-171. (Pubitemid 351645123)
117. Utell MJ, Maxim LD. Refractory ceramic fiber (RCF) toxicity and epidemiology: a review. Inhal Toxicol 2010; 22:500-521.
118. Watterson A, Gorman T, Malcolm C, et al: The economic costs of health service treatments for asbestos- related mesothelioma deaths. Ann N Y Acad Sci 2006; 1076: 871-881. (Pubitemid 44955315)
119. Whitehouse AC, Black CB, Heppe MS, et al: Envi ronmental exposure to Libby Asbestos and mesotheliomas. Am J Ind Med 2008; 51: 877-880.
120. Yang H, Rivera Z, Jube S, et al: Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. PNAS 2010; 28: 12611- 12616.